<DOC>
	<DOCNO>NCT01134822</DOCNO>
	<brief_summary>The overall aim study develop test predicts prognosis IPF ( Idiopathic Pulmonary Fibrosis ) could use determine whether new treatment IPF likely work .</brief_summary>
	<brief_title>Prospective Study Fibrosis In Lung Endpoints ( PROFILE - Central England )</brief_title>
	<detailed_description>The overall objective study - Discover validate novel biomarkers gene expression profile use subsequent intervention study patient IPF - To prospectively validate panel previously publish biomarkers patient well characterized idiopathic fibrosing lung disease - Investigate genetic association epigenetic modification affect disease severity progression - Prospectively evaluate longitudinal disease behaviour patient IPF NSIP view develop composite clinical end-points subsequent use intervention study patient IPF Biomarkers use follow purpose identify : - Identify patient ( Diagnostic ) ( e.g . discriminate health disease ) - Correlate disease severity ( extent disease , stag disease ) - Predict clinical progression ( Prognostic ) ( stable v progressive disease ) - Track response therapy ( Theranostic ) - Predict response know efficacious treatment &amp; Correlates change clinical endpoints/mortality/quality life - Predict risk exacerbation ( could use prevent exacerbation reduce severity ) - Correlate complication and/or comorbidities ( e.g . biomarkers PAH , GER IPF , etc )</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>A diagnosis IPF use consensus criterion ( 32 ) NSIP . Between age group 1885 year . Sub classify Mild ( TLCO &gt; 60 ) , Moderate ( TLCO 4060 ) , Severe ( TLCO &lt; 40 ) . People volunteer undergo bronchoscopy research People IPF/NSIP ( i.e . Hypersensitivity Pneumonitis , Sarcoidosis ) People give inform consent . People consider bronchoscopy , contraindication undergoing procedure set British Thoracic Society guideline ( Thorax 2001 ; 56 : suppl I : i1i21 ) . These part study undergo BAL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>IPF</keyword>
	<keyword>Lung Fibrosis</keyword>
	<keyword>Biomarkers</keyword>
</DOC>